Venus Medtech (Hangzhou), Inc. Class H
VMTHF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$57.93M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $57.93 Million |
|---|---|
| Enterprise Value | $174.06 Million |
| Earnings per Share | $-0.91 |
| Beta | 1.15 |
| Outstanding Shares | 437,897,443 |
Return
| Return on Equity | -72.23% |
|---|---|
| Return on Assets | -49.57% |
| Return on Invested Capital | -55.25% |
Valuation & Multiples
| P/E Ratio | -0.78 |
|---|---|
| PEG | -1.87 |
| Price to Sales | 0.13 |
| Price to Book Ratio | 0.04 |
| Enterprise Value to Revenue | 0.26 |
| Enterprise Value to EBIT | -0.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.17 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Venus Medtech (Hangzhou) Inc.
557 employees
CEO: Hou-Sen Lim
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic h...